Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial

医学 临床终点 内科学 肿瘤科 放化疗 癌症 实体瘤疗效评价标准 腺癌 代理终结点 临床试验 化疗 临床研究阶段 胃肠病学 外科
作者
Jia Wei,Xiaofeng Lu,Qin Liu,Yao Shi Fu,Song Liu,Lin Li,Fangcen Liu,Xiangshan Fan,Ju Yang,Yang Yang,Yang Chun Zhao,Wenxian Guan,Baorui Liu
出处
期刊:Cancer management and research [Dove Medical Press]
卷期号:Volume 14: 2007-2015 被引量:13
标识
DOI:10.2147/cmar.s355687
摘要

Purpose: Concurrent chemoradiotherapy (cCRT) is the mainstay therapy of locally advanced gastric (G) and gastroesophageal junction (GEJ) cancers with a poor prognosis. Programmed cell death receptor-1 (PD-1) inhibitor has been approved and recommended to treat ≥3 line G/GEJ patients. A significant clinical benefit of PD-1 inhibitors in addition to cCRT has been observed in locally advanced lung cancer. Sintilimab, a humanized IgG4 monoclonal antibody with high affinity and specificity for PD-1, has shown promising efficacy with an overall response rate of 85% in combination with chemotherapy in gastric cancer in a phase Ib study (NCT02937116). Patients and Methods: SHARED is a prospective, multicentre, single-arm Phase II trial in China, exploring the efficacy of sintilimab in combination with cCRT in locally advanced G/GEJ adenocarcinoma. According to a Simon optimal two-stage clinical design, 34 patients will be enrolled. All the eligible patients will receive one cycle of induction chemotherapy (S-1 plus nab-PTX) combined with sintilimab, followed by cCRT (radiotherapy plus nab-PTX) combined with sintilimab. Prior to the surgery, patients will receive another cycle of chemotherapy (S-1 plus nab-PTX) combined with sintilimab. In the adjuvant setting, all participants will be treated with 3 cycles of chemotherapy (S-1 plus nab-PTX) combined with sintilimab. The primary endpoint is the rate of pathological complete response (pCR). The secondary endpoints include disease-free survival (DFS), major pathological response (MPR), R0 resection rate, surgical AEs, overall survival (OS), event-free survival (EFS), and safety profile. Moreover, the prognostic value of tumor biomarkers and immune biomarkers will be explored. Conclusion: SHARED is designed to primally evaluate the efficacy and safety of sintilimab in combination with cCRT in locally advanced G/GEJ cancers and to prospectively validate the prognostic value of tumor biomarkers and immune biomarkers.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
活力的香发布了新的文献求助10
1秒前
然然完成签到,获得积分10
1秒前
yinxinyi发布了新的文献求助10
1秒前
CodeCraft的应助被ljs采纳,获得10
2秒前
2秒前
顺利曼易发布了新的文献求助10
2秒前
Xh的应助被rice采纳,获得10
2秒前
终梦发布了新的文献求助10
2秒前
3秒前
ddz完成签到,获得积分10
3秒前
DW的应助被Jimmy Ko采纳,获得10
3秒前
未了发布了新的文献求助10
3秒前
田様的应助被ccc采纳,获得10
3秒前
quruijie完成签到,获得积分10
4秒前
weiguangjing发布了新的文献求助10
4秒前
吃葡萄不吐葡萄皮的应助被zzer采纳,获得10
4秒前
4秒前
5秒前
5秒前
6秒前
落云渊完成签到,获得积分10
6秒前
7秒前
大个的应助被电生理搬运工采纳,获得10
7秒前
深情安青的应助被qearl采纳,获得10
8秒前
实验室发布了新的文献求助10
8秒前
幸福乐蕊完成签到,获得积分10
9秒前
顺心行天完成签到,获得积分10
9秒前
何hs完成签到,获得积分10
9秒前
朱雀发布了新的文献求助10
9秒前
li07完成签到 ,获得积分10
9秒前
wangwang完成签到 ,获得积分10
9秒前
9秒前
夏侯远望完成签到,获得积分10
10秒前
Duan发布了新的文献求助10
10秒前
傲柏完成签到 ,获得积分10
10秒前
haihuhu完成签到 ,获得积分10
10秒前
稳重擎苍发布了新的文献求助30
10秒前
重要莹发布了新的文献求助10
10秒前
星辰大海的应助被未了采纳,获得10
10秒前
金2022完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253